chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Starting 8 hours after my vaccine, I got chills, body aches, low-grade fever, headache, very sore arm, and felt horrible.  This continued for the next 24 hours (I didn't take any Tylenol or Advil, and I didn't do my usual exercise routine, I just laid low).  It started getting better finally 48 hours after the vaccine.
B/P 130/70 9:45. Stomach ache. Dizziness. Tired. Follow up information received. Date of vaccination 11/13/09 at 10AM - Adverse event onset 11/13/09 at 11AM.
Delayed Anaphalaxsis; This is a spontaneous report from a contactable consumer. A 17-year-old male patient (reporter's son) received BNT162b2 (PFIZER-BIONTECH COVID-19 VACCINE), first dose, via an unspecified route of administration, administered in arm left on 15Aug2021 13:45 at the age of 17 years old, as single dose for covid-19 immunisation. Medical history included seasonal allergies (non medicated), covid-19, ADD (attention deficit hyperactivity disorder, non medicated). There were no concomitant medications. There was no other vaccine in four weeks or other medications in two weeks. The patient experienced delayed anaphalaxsis on 16Aug2021 17:45. Event resulted in Doctor or other healthcare professional office/clinic visit, Emergency room/department or urgent care, Life threatening illness (immediate risk of death from the event). Treatment Epi, IM Benadryl, IM Steroid IM anxiolytic, IV fluids was received for the event. The outcome of the event was recovering. Since the vaccination, the patient had not been tested for COVID-19.  The lot number for the vaccine BNT162B2 was not provided and will be requested during follow up.
Substantial and painful blood clots in my left arm and left upper chest and shoulder. These are persisting and getting worse, not better, over time. I also had blood clots from the J&J vaccine, in my left leg especially, but that problem didn't last as long. I am uninsured due to medical disability and living where the disability awarding system is disfunctional and the governors reject government money for insurance expansion, so I found a new free clinic online. I will see them on Friday afternoon hopefully and ask for blood thinners. Until then I am taking naproxen sodium and turmeric to manage pain / improve circulation.
had right neck pain and difficulty swallowing after 6 days of 2nd dose. went to ER,CT scan done,founf multile thyroid nodules on BL side.saw endocrynologist done ultrasound and FNAB.TSH level too low and found inflamation.started taking prednisone.
Vaccine given to a 17-year, 11-month-old when EUA is for 18 years and older.
Information has been received from a physician and a practice manager referring to a patient of unknown age and gender. On 13-JUL-2016 the patient was vaccinated with an improperly stored dose of PNEUMOVAX 23 (lot # L040178, expiration date 18-AUG-2017). This specified lot number vaccine was exposed to temperature excursion one time. The total cumulative excursion time was 48 hours with the lowest recorded temperature of 34 Fahrenheit degree. The storage criteria and the type of excursion for this vaccine was refrigerator (R). No adverse event was reported. This is one of several reports received from the same source. Additional information has been requested.
Patient felt extremely under the weather and requested we report her side effects. She has a mild fever of 99 degrees F. Patient had chills and severe aches and pains. She stated it felt similar to the COVID booster and had never experienced these side effects with the flu shot
Swelling, redness, slight numbness at the finger tips.  Recommend NSAIDS for management of swelling and soreness.
1. Follow up call to patient on 8/26/10. Was told by patient's wife that she thought patient had signs of shingles on his forehead. Refer the patient to his primary care doctor.  2. Patient saw Dr. on 8/27 who suspected shingles and prescribe him Zovirax 400mg. 3. Talked to wife on 9/4/10 and was told patient had seen doctor and was on Zovirax and seems to be doing better. The shingles lesions/rash was only on his forehead and scalp.
Seizure <5min, generalized tonic-clonic-evaluated in emergency room. Neg CT, lab. Started on Keppra empirically. EEG negative.
Diarrhea x 3 weeks following Rotateq vaccine administration.  No treatment was prescribed by client's physician.
hives in 10mins; rash the day p/inj & itchy-all over body, inc eyes; lips, nose, face swollen 5 days later; hard time swallowing 6th day went to ER Medrol dose pak, DPH inj to IV's x 2;
Patient experienced pain at the time of injection. Increasing discomfort and decreasing mobility everyday since. Some swelling in the area; no redness. Unable to lift arm against gravity.
Joint pain; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP).  A 46 year-old male patient received bnt162b2 (BNT162B2), administration date 19Sep2021 (Lot number: FF2588) at the age of 46 years as dose 1, single for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. he following information was reported: ARTHRALGIA (non-serious) with onset 2021, outcome "unknown", described as "Joint pain". Therapeutic measures were not taken as a result of arthralgia.  Additional information: The report was not related to study or programme. Reporter (patient's partner) mentioned that the patient had received his first dose not too long ago and now he had joint pain, where its onset was reported as two days ago (date unspecified). Patient had received only the first dose and had not received the second dose. Reporter stated no trial vaccinations was received when asked about prior vaccination details. No lab test and investigation assessment was reported.  No follow-up attempts are possible. No further information is expected.
Blood sugar levels of 178 after receiving the second dose of the vaccine; This spontaneous case was reported by a consumer and describes the occurrence of HYPERGLYCAEMIA (Blood sugar levels of 178 after receiving the second dose of the vaccine) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced HYPERGLYCAEMIA (Blood sugar levels of 178 after receiving the second dose of the vaccine). At the time of the report, HYPERGLYCAEMIA (Blood sugar levels of 178 after receiving the second dose of the vaccine) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood glucose fluctuation: 178 (Inconclusive) After the second shot it was 178..         Concomitant medication information was not reported. Treatment information as not reported. Action taken with mRNA-1273 (Moderna COVID-19 Vaccine) is considered as not applicable.
recently diagnosed with suspected autoimmune disease Sarcoidosis but no coughing involved - mainly skin; a slight headache; a month after the 2nd shot I ran a fever that lasted 3 weeks. the first week the fever would reach 103.5 and second week 101 and 3rd week between 99.5 and 100.5; A week after the 2nd shot I felt lethargic and without ability to focus - eyes also were achy.  This lasted for a few weeks but no fever.; A week after the 2nd shot I felt lethargic and without ability to focus - eyes also were achy.  This lasted for a few weeks but no fever.; A week after the 2nd shot I felt lethargic and without ability to focus - eyes also were achy.  This lasted for a few weeks but no fever.; This is a spontaneous report from a contactable consumer (patient). A 58-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE lot/batch number and expiration date not reported) via an unspecified route of administration, administered on the left arm on 26Mar2021 13:00 as 2nd dose, single for COVID-19 immunisation. Medical history included autoimmune disease suspected. Concomitant medications included losartan; hydrochlorothiazide; atorvastatin and tadalafil (TADAL). The patient previously received first dose of BNT162B2 on 06Mar2021 for COVID-19 immunization (first dose, administration time: 11:00 PM, anatomical location: arm left). A week after the 2nd shot (Apr2021), patient felt lethargic and without ability to focus - eyes also were achy. This lasted for a few weeks but no fever. Event resulted to a Doctor or other healthcare professional office/clinic visit; no treatment received. A month after the 2nd shot (26Apr2021 01:00 AM) patient ran a fever that lasted 3 weeks. The first week the fever would reach 103.5 and second week 101 and 3rd week between 99.5 and 100.5. Eyes still hurt and fever was controlled by aspirin during day. It was not a normal fever and he did have a slight headache. Recently diagnosed with suspected autoimmune disease Sarcoidosis but no coughing involved - mainly skin. He felt fine now. Note extensive blood tests and sonograms/xrays turned up nothing that would cause such a prolonged fever. "I've never run a fever for more than 4 or 5 days. I also hardly ever get sick". Events were reported as non-serious: did not result in death, was not life-threatening, did not cause/prolonged hospitalization, was not disabling/incapacitating and did not cause congenital anomaly/birth defect. Covid test post vaccination: Nasal Swab negative and blood test negative both on 26Apr2021. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Outcome of the event sarcoidosis was unknown, while recovered on an unspecified date for the other events.   Information on the lot/batch number has been requested.
giving a 74 year old patient a dose of ActHib was out of indication with no reported adverse event; Initial information received on 20-Oct-2022 regarding an unsolicited valid non-serious case received from a physician.  This case involves a 74 years old and unknown gender patient who had a dose of HIB (PRP/T) VACCINE [ACT-HIB] was out of indication with no reported adverse event.   The patient's past medical history, medical treatment(s), concomitant medication, vaccination(s) and family history were not provided.   On 20-Oct-2022, the patient received an unknown dose of suspect HIB (PRP/T) VACCINE Powder and solvent for solution for injection(strength, lot number and expiry date was unknown) via intramuscular route in unknown administration site for prophylactic vaccination.  On 20-OCT-2022 the patient developed a non-serious event of giving a 74 year old patient a dose of acthib was out of indication with no reported adverse event (product administered to patient of inappropriate age) (Latency: same day) following the administration of HIB (PRP/T) VACCINE.  Action taken : not applicable.  Outcome: Unknown  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
11/03/2021 I woke up with a very painful swollen gland/lymph node in my left armpit, it is still the same. On 11/04/2021 my entire left side, upper arm, armpit, and left breast are swollen, also a rash in all those areas. I called my doctor 11/05/2021 and I was advised to just put ice on it. It still has not gone down all the way to this day.
Pain around injection site; Swelling around injection site; Rash around injection site and an inch down; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (Pain around injection site), VACCINATION SITE SWELLING (Swelling around injection site) and VACCINATION SITE RASH (Rash around injection site and an inch down) in a 64-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 08-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 06-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 07-Mar-2021, the patient experienced VACCINATION SITE PAIN (Pain around injection site), VACCINATION SITE SWELLING (Swelling around injection site) and VACCINATION SITE RASH (Rash around injection site and an inch down). On 10-Mar-2021, VACCINATION SITE PAIN (Pain around injection site) and VACCINATION SITE SWELLING (Swelling around injection site) had resolved. At the time of the report, VACCINATION SITE RASH (Rash around injection site and an inch down) outcome was unknown.            No concomitant medication was provided  Treatment medication was not provided  Action taken with mRNA-1273 Moderna vaccine was Not Applicable
SUSPECTED IMMUNOLOGICAL VACCINE FAILURE; This spontaneous report received from a consumer concerned a female of unspecified age, race and ethnicity. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown, expiry: unknown) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported.  On an unspecified date, the patient experienced suspected immunological vaccine failure. Laboratory data (dates unspecified) included: Antibody test (NR: not provided) negative. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of suspected immunological vaccine failure was not reported. This report was serious (Other Medically Important Condition).; Sender's Comments: V0:20211011936-Covid-19 vaccine ad26.cov2. s-Suspected immunological failure. This event(s) is considered not related. The event(s) has an unknown/unclear temporal relationship, is unlabeled, and has unknown scientific plausibility. There are other factors more likely to be associated with the event(s) than the drug. Specifically: SPECIAL SITUATIONS
This spontaneous report was received from a nurse practitioner and refers to an adult patient of unknown gender. No information about the patient's medical history, concurrent conditions, drug reactions or allergies and concomitant therapies was provided. On 16-JAN-2017, the patient was inadvertently vaccinated with PROQUAD injection, lot# reported as M023718, expiration date: 09-AUG-2018 (dose and route of administration were not reported) instead of intended dose of M-M-R II. on the same day, the patient was vaccinated also with VARIVAX injection (lot#, expiration date, dose and route of administration were not reported). The error occurred because the medical assistant who administered the vaccines did not look closely enough what she selected to administer and confused the vaccines. No adverse effects were reported. No dose of M-M-R II was administered. No product complaint was involved. Additional information has been requested.
Fever; chills; sweating; nausea; elevated BP; pale face; fatigue; loss of appetite; This is a spontaneous report from a contactable Other HCP. A 32-year-old male patient reported that he received second dose of  BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number EL1283), at single dose on 09Jan2021 at 03:30 PM for COVID-19 immunization. The patient had received first dose of BNT162B2 (lot number: EJ1685)  on 19Dec2020. O n 12Dec2020 the patient was Covid tested via Nasal Swab COVID-19 PCR and the result was negative. On 10Jan2021 at 12:30 PM the patient experienced fever, chills, sweating, nausea, elevated BP, pale face, fatigue, loss of appetite. No treatment was received. The patient did not have Covid prior vaccination.  At the time of reporting the patient had not recovered.
Received MMR and Varivax on 04/02/2002. On 04/06 developed temp 100 deg. F. On 04/07 temp 101-102 deg. F. persisted 04/08-04/09. No other symptoms. On 04/10 had seiaure with loss of consciousness. Diagnosed febrile seizure.
other zoster related injuries; shingles; varicella type rash; This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a currently approximately 70-year-old patient of unknown gender. Medical history, concurrent conditions and concomitant medications were not provided.  On or about 16-APR-2013, the patient was administered the zoster vaccine live (ZOSTAVAX) (dose, route of administration, site of administration and lot # were not provided), by a healthcare provider, for the long-term prevention of shingles and zoster-related conditions. On unknown dates, the patient was treated for the following injuries resulting from the patient's zoster vaccine live (ZOSTAVAX) use: shingles, varicella type rash and other zoster related injuries. The patient claimed damages as a result of: injury to themselves, loss of consortium and  loss of services. The outcome of the events was not provided.  The lawyer felt the events were related to zoster vaccine live (ZOSTAVAX).
COVID related hospitalization after receiving COVID vaccine: Janssen 8/5/2021  Tested positive for COVID 3/2/22  Pt had covid previously in December 2021  Received Monoclonal ab treatment 12/14/2021(casirivimab-imdevimab 600mg)   Admitted 3/8/22 to Hospital  Presented with worsening shortness of breath and cough. 10 days prior started having dry cough, body aches, chills and was evaluated-put on steroids and antibiotics assuming it was an asthma exacerbation.   CT chest on admission showed ground-glass opacities in the right upper lobe, in bilateral lower lobes  Presume COVID-19 viral pneumonia/asthma exacerbation  Given IV solumedrol   budesonide-formoterol, montelukast and mucinex BID with improvement     Discharged 3/11/22 on prednisone taper and MUCINEX along with home meds
pt recv vax; local edema & erythema on lt arm at site w/in 12 hr; lt arm very sore, some progression next day; devel v & SOB 48 hr p/ shot; improved gradually;
Disruption in menstrual cycle; I have been tracking my 'cycle' for 6 months, it has been 28 days on the mark. Following the vaccine my first period was two weeks late followed by spotting 2 weeks later. Now on cycle 2 I am 3 days late with severe pressure and cramping. I discussed the irregularity with my nurse practitioner who said she could not say that the two were related but has heard this from other patients. I currently have no treatment plan or course of action except to 'wait it out'.
Patient developed a fever the day of his vaccines (10/20/2020) and it has continued x 3 days.  Patient has had a decrease in appetitie and one episode of diarrhea.  Patient now has a subtle reticular rash on his trunk and arms.
No Adverse Event; Moderna Bivalent vaccine was administered Beyond use by date to 6 patients.; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Moderna Bivalent vaccine was administered Beyond use by date to 6 patients.) and NO ADVERSE EVENT (No Adverse Event) in an 86-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 042H22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 12-Jan-2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 12-Jan-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced EXPIRED PRODUCT ADMINISTERED (Moderna Bivalent vaccine was administered Beyond use by date to 6 patients.). On an unknown date, the patient experienced NO ADVERSE EVENT (No Adverse Event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Moderna Bivalent vaccine was administered Beyond use by date to 6 patients.) and NO ADVERSE EVENT (No Adverse Event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No Adverse Event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (Moderna Bivalent vaccine was administered Beyond use by date to 6 patients.).    Concomitant medications were not reported.                                       No treatment information was provided by the reporter.
Fainted, fell off chair. Regained consciousness after 30 seconds. Reported that vision became blurry and then fainted. EMS responded with EKG and BP normal, Heart Rate was 106. Left facility after 40 minutes and walked home. approx 4 blocks.
77 y.o. female with anxiety, diabetes mellitus type 2, hyperlipidemia hypertension, bipolar disorder, parkinsonism recently diagnosed brain mass was brought to ER from a facility for facial swelling and pain. Patient also noted to have developed hypoxia and multifocal pneumonia with COVID19 with possible aspiration pneumonia. She was initially on high flow but then improved and was able to transfer out of the ICU. has now been accepted to a skilled nursing facility as her main issue now is getting stronger with physical therapy.
DTaP given on 12/7/2001. On 12/08/2001 at left deltoid pt with redness and swelling. On 12/09/2001 pt with increased itching, erythema and induration. Size about 4 by 4 cm per Mom. Benadryl 1 tsp given once with decreased itching. On 12/10/2001 AM noted to have decreased erythema and swelling but with erythema ring. Erythema multiforme with rash around original...
Pt had Pneumococcal 23 and SHINGRIX on 8/23/18. Back in today with swollen face and eyes. Denies SOA. Symptoms started yesterday. Dr. thinks from SHINGRIX.
Initial report was received from a consumer on 29 September 2010. A female patient (age and past medical history not reported0, had received FLUZONE, lot number UH181AB (date, site and route of administration not reported) and an unspecified amount of time later, experienced swelling and warmth with pain down the arm, "from fingers to armpit". No further information was available at the time of the report. The patient's outcome was not reported. Documents held by sender: none.
herpetic keratitis; chills; fever; This case was reported by a other health professional via call center representative and described the occurrence of herpetic keratitis in a 77-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Zostavax (received 6 years ago).   On 18th June 2019, the patient received the 1st dose of Shingrix. On 20th June 2019, 2 days after receiving Shingrix, the patient experienced herpetic keratitis (serious criteria GSK medically significant), chills and fever. On an unknown date, the outcome of the herpetic keratitis, chills and fever were unknown.   It was unknown if the reporter considered the herpetic keratitis, chills and fever to be related to Shingrix.  Additional information was provided as follows: The patient received Shingrix and experienced severe chills, fever, and herpetic keratitis. The reporter did not have the lot number and expiry date.  The reporter consented to follow up.
My arm hurts and has a rash. I had a fever chills all the symptoms of the flu.